May 10, 2017 12:05 pm UTC| Business
SAN DIEGO, May 10, 2017 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced...
Bellerophon Announces $3.0 Million Registered Direct Offering
May 10, 2017 12:04 pm UTC| Business
WARREN, N.J., May 10, 2017 -- Bellerophon Therapeutics,Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has entered into a definitive agreement with a single institutional investor...
Bellerophon Announces $3.0 Million Registered Direct Offering
May 10, 2017 12:04 pm UTC| Business
WARREN, N.J., May 10, 2017 -- Bellerophon Therapeutics,Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has entered into a definitive agreement with a single institutional investor...
Bellerophon Announces $3.0 Million Registered Direct Offering
May 10, 2017 12:04 pm UTC| Business
WARREN, N.J., May 10, 2017 -- Bellerophon Therapeutics,Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it has entered into a definitive agreement with a single institutional investor...
Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update
May 10, 2017 12:04 pm UTC| Business
WEST LAFAYETTE, Ind., May 10, 2017 -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial...
Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update
May 10, 2017 12:04 pm UTC| Business
WEST LAFAYETTE, Ind., May 10, 2017 -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial...
Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update
May 10, 2017 12:04 pm UTC| Business
WEST LAFAYETTE, Ind., May 10, 2017 -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial...